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CASE REPORT
Acute liver failure and seizures as a 
consequence of regorafenib exposure 
in advanced rectal cancer
Soundouss Raissouni1*, Zarqa Quraishi1, Mohammed Al‑ghamdi1,2, Jose Monzon1, Patricia Tang1 
and Michael M. Vickers1
Abstract 
Background: Regorafenib is a multi‑targeted tyrosine kinase inhibitor approved for use in refractory colorectal can‑
cer. We report the first case of seizures secondary to acute liver failure, shortly after initiation of regorafenib in a patient 
with advanced rectal carcinoma.
Case presentation: A 64 year‑old Caucasian female presented with confusion and generalized tonic–clonic seizures, 
5 days after initiation of regorafenib for advanced rectal cancer. Investigations revealed significant elevations in biliru‑
bin and alanine aminotransferase. No other cause for seizures and liver dysfunction were found. After interruption of 
regorafenib, no further seizures occurred, the symptoms of confusion resolved and liver function returned to normal.
Conclusions: We report the first case of regorafenib‑induced acute liver failure resulting in seizures. We suggest early 
monitoring for side effects, both clinically and biochemically after initiation of regorafenib.
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Background
Regorafenib is a novel oral multi-kinase  inhibitor  that 
targets oncogenesis, tumor angiogenesis and the tumor 
microenvironment [1]. In cellular kinase phosphorylation 
assays, regorafenib inhibited VEGFR-1, -2 and -3, FGFR1, 
PDGFR-b, KIT, RET, RAF-1, BRAF and BRAFV600E [2, 
3]. Currently, regorafenib is indicated as monotherapy for 
the treatment of refractory advanced colorectal cancer 
(ACRC), based on a large phase III randomised clinical 
trial (CORRECT) [4] as well as in gastrointestinal stromal 
tumors (GIST) after failure of imatinib and sunitinib [5]. 
The most common treatment-related adverse events (any 
grade) with regorafenib reported in the CORRECT trial 
included hand-foot skin reaction (47  %), fatigue (47  %), 
diarrhea (34  %), anorexia (30  %), voice changes (29  %), 
hypertension (28  %) mucocitis (27  %), and rash (26  %). 
Liver function abnormalities were also more common in 
patients receiving regorafenib and included elevations in 
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST) and bilirubin [4]. One case of fatal liver dys-
function was also observed. Conversely, central nervous 
system (CNS) toxicity has rarely been reported with this 
agent [3, 6]. We report a case of acute liver failure com-
plicated by seizure shortly after initiation of regorafenib 
in a patient with advanced rectal carcinoma.
Case presentation
A 64 year-old Caucasian female was followed at our insti-
tution since June 2009 for rectal cancer. Her past medi-
cal history was remarkable for acute kidney injury of 
unknown etiology in 2009 (resolved), prior smoking his-
tory and moderate alcohol intake for 35 years (discontin-
ued in 2009). Initial staging of her rectal cancer revealed a 
cT4N2M0, and she received neoadjuvant chemoradiation 
(45 Gy concurrent with continuous infusional fluoroura-
cil at a dose of 225  mg/m2 per day) from July–August 
2010. Resection of the primary tumor was attempted in 
November 2010, but was unsuccessful due to progressive 
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local disease and a diverting colostomy was placed. A 
Positron emission tomography/computed tomography 
(PET/CT) scan in September 2010 revealed pulmonary 
and liver metastasis. Subsequent lines of chemotherapy 
included FOLFIRI (folinic acid, fluorouracil and irinote-
can) plus bevacizumab with initially stable disease. At 
progression, she received FOLFOX (folinic acid, fluoro-
uracil and oxaliplatin) for 4 months followed by 15 cycles 
of Panitumumab (KRAS wild type tumor) with initially 
stable disease. Throughout her therapies there was no 
evidence of CNS toxicity or liver toxicity and the patient 
maintained an ECOG performance status of 0. In Janu-
ary 2014, re-staging scans showed progressive local and 
distant disease. The patient initiated regorafenib at the 
dose of 120 mg daily (25 % dose reduction as patient con-
cerned about potential toxicities). Five days after starting 
regorafenib she presented to the emergency department 
with diarrhea, three episodes of generalized tonic–clonic 
seizures and decreased level of consciousness. On admis-
sion the patient was afebrile, mildly jaundiced, had a 
blood pressure of 148/90  mmHg, heart rate of 90 beats 
per minute, oxygen saturation of 97 % on room air, and 
found to have grade 3 encephalopathy, and a Glasgow 
coma score of 10. No other focal neurologic deficits 
were identified. Admission blood work revealed normal 
electrolytes aside from mild hypokalemia of 3.1  mEq/L 
and normal renal function. There was evidence of grade 
3 (Common Terminology Criteria for Adverse Events 
(CTCAEv3.0)) hyperbilirubinemia (80 umol/L), grade 4 
elevation of ALT (1290 U/L), grade 1 elevation in alka-
line phosphatase (267 U/L) and grade 3 International 
normalized ratio (INR) elevation at 2.6. Complete blood 
count was unremarkable except for a leukocytosis of 
22 × 109/L. Blood cultures and urine cultures were nega-
tive and initial enhanced computed tomography of the 
head was unremarkable. Initial management, before 
obtaining the results of the initial workup, included dis-
continuation of regorafenib, administration of benzo-
diazepines, a loading dose of phenytoin, and treatment 
with acyclovir and broad spectrum antibiotics. Cytology 
from a lumbar puncture was negative (cytology negative 
and negative for infectious encephalitis) and magnetic 
resonance imaging (MRI) of the brain revealed small 
areas of increased T2 signal seen in the hemispheric sulci 
in the region of the occipital poles, right frontal convex-
ity, and right parietal parafalcine location, but did not 
reveal the classic changes of reversible posterior leukoen-
cephalopathy syndrome (RPLS). Electroencephalogra-
phy (EEG) revealed runs of frontal intermittent rhythmic 
delta activity and rare triphasic waves. In addition, there 
was generalized slowing consistent with diffuse abnor-
mal brain function suggestive of a moderate encepha-
lopathy related to a metabolic etiology. A CT scan of 
the abdomen did not show any sign of biliary obstruc-
tion. Despite only having hypokalemia at presentation, 
she required daily electrolyte replacement to correct 
grade 3 hypomagnesemia, grade 2 hypocalcemia, grade 4 
hypokalemia and grade 3 hypophosphatemia. As a conse-
quence of electrolytes abnormalities, electrocardiogram 
revealed prolonged QTc at 519 ms, T wave inversion in 
inferior and lateral leads. Liver function at discharge (day 
10) improved significantly with normalization of bili-
rubin (14 umol/L) and mild elevations in ALT (54 U/L) 
and INR (1.2) (Figs. 1, 2). Seventeen days after admission, 
ALT (37 U/L) and bilirubin (16 umol/L) returned to nor-
mal. Confusion and memory loss resolved and there were 
no further seizures after the day of admission.
Discussion
Acute liver failure (ALF) is a syndrome involving sudden 
and severe loss of hepatocyte function due to hepato-
cyte necrosis [7]. This diagnosis is characterized by acute 
liver dysfunction, hepatic encephalopathy and coagu-
lopathy. Patients with rapid onset of jaundice are at the 
highest risk of cerebral complications, such as asterixis, 
delirium, seizures and coma. The exact pathophysiology 
of these cerebral effects is yet to be determined, however 
may involve cerebral edema/astrocyte swelling, ammonia 
accumulation, oxidative stress and blood–brain barrier 
dysfunction [8]
Our case is consistent with regorafenib exposure lead-
ing to acute liver failure and subsequent hepatic enceph-
alopathy and seizures. Prior to initiation of regorafenib, 
the patient’s liver function was normal, but acutely dete-
riorated with significant elevations in ALT, bilirubin and 
the development of hepatic encephalopathy and coagu-
lopathy. In addition, the MRI and EEG findings were not 
consistent RPLS which was considered in this case and 
has been reported with other anti-angiogenic agents [9]. 
Recently, Zaw et  al. [10] reported a case of grand mal 
seizure shortly after initiation of regorafenib in a patient 
treated with metastatic colon carcinoma. Investigations 
in that case confirmed the diagnosis of RPLS with charac-
teristic MRI findings. In addition, this patient presented 
with elevated blood pressure (>200/100  mmHg) in the 
absence of liver dysfunction [10]. In contrast, our patient 
was not overly hypertensive on admission, did not have 
visual defects nor was the MRI suggestive of RPLS. One 
seizure was also reported in the CORRECT trial although 
the details of this case are unknown [4]. To our knowl-
edge, our case is the first to describe regorafenib-induced 
seizure as a result of acute liver failure.
In the CORRECT trial, liver function test abnormalities 
were common and included elevations in ALT (any grade: 
45.2 %; grade 3/4: 5.5 %), AST (any grade: 65 %; grade: 3/4 
5.9 %) and bilirubin (any grade: 44.6 %; grade: 3/4 12.2 %) 
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(see Web appendix, Online Table 6) [4]. One patient with 
liver metastases had progressive liver dysfunction 43 days 
after initiation of regorafenib with a fatal outcome. In 
both the CORRECT and GRID trials liver function was 
monitored every 2 weeks, with closer monitoring of AST, 
ALT and bilirubin (twice weekly for 2  weeks and then 
weekly for at least 4 weeks) after the occurrence of liver 
function abnormalities. Despite an initial dose reduction, 
our patient experienced acute liver failure 5  days after 
starting regorafenib. Toxicity of this degree would not be 
captured with the current recommendations of every two 
weekly blood monitoring and as such, we suggest close 
monitoring of patients after initiation of regorafenib with 
early clinical and laboratory assessment within 3–5 days.
Conclusion
In conclusion, we report a case of regorafenib-induced 
acute liver failure precipitating seizures in advanced rec-
tal cancer. Since regorafenib is indicated in the refractory 
setting of colorectal cancer treatment and has shown a 
Fig. 1 Alanine aminotransferase (ALT) level variations (U/L)
Fig. 2 Bilirubin level variations (umol/L)
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modest survival benefit, consideration of patients’ qual-
ity of life and avoidance of significant side effects must be 
paramount. Close monitoring for side effects, both clini-
cally and biochemically is indicated.
Consent
Written informed consent was obtained from the patient 
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for 
review by the Editor-in-Chief of this journal
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